Clinical Trial Detail

NCT ID NCT01751425
Title Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center|Incyte Corporation
Indications

leukemia

chronic myeloid leukemia

Therapies

Ruxolitinib

Age Groups: adult

No variant requirements are available.